ALK and laryngotracheoesophageal cleft: Despite advancement in knowledge of the molecular mechanisms involved in LC, this tumor is still characterized by an unfavorable prognosis, and the current therapeutic options for LC, including surgery, radiation therapy, chemotherapy and molecularly targeted therapy (e.g., epidermal growth factor receptor or anaplastic lymphoma kinase inhibitors and immunotherapy) [2,4] are unsatisfactory, resulting in a dismal 5-year survival rate and fatal outcomes of LC patients [5].